(19)
(11) EP 3 880 697 A2

(12)

(88) Date of publication A3:
27.08.2020

(43) Date of publication:
22.09.2021 Bulletin 2021/38

(21) Application number: 19817875.8

(22) Date of filing: 15.11.2019
(51) International Patent Classification (IPC): 
C07K 14/705(2006.01)
C07K 16/28(2006.01)
 C07K 16/22(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 14/515; C07K 16/28; C07K 2317/31; A61P 35/00; A61K 2039/505; C07K 16/22; C07K 2317/24
(86) International application number:
PCT/US2019/061651
(87) International publication number:
WO 2020/102644 (22.05.2020 Gazette 2020/21)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 15.11.2018 US 201862767923 P

(71) Applicant: OncoMed Pharmaceuticals, Inc.
Redwood City, CA 94063 (US)

(72) Inventors:
  • BRUNNER, Alayne Lisette
    Redwood City, California 94063 (US)
  • CAI, Suqin
    Redwood City, California 94063 (US)

(74) Representative: CMS Cameron McKenna Nabarro Olswang LLP 
Cannon Place 78 Cannon Street
London EC4N 6AF
London EC4N 6AF (GB)

   


(54) METHODS AND MONITORING OF TREATMENT WITH VEGF/DLL4 BINDING AGENT